John Ioannidis

See the following -

From Crowdfunding To Open Access, Startups Are Experimenting With Academic Research

Danny Crichton | TechCrunch | March 3, 2014

These days may well be the next golden age for universities, and startups are leading the way. For institutions that can feel much like their counterparts from a thousand years ago, universities have witnessed breathtaking change in just a handful of years. Read More »

How Google Plans to Reinvent Healthcare

Cheryl Swanson | The Motley Fool | September 3, 2016

Glucose-monitoring contact lenses for diabetics, wrist computers that read diagnostic nanoparticles injected in the blood stream, implantable devices that modify electrical signals that pass along nerves, medication robots, human augmentation, human brain simulation -- the list goes on. That's not an inventory of improbable CGI effects from the latest sci-fi movie, it's a list of initiatives being tackled by Alphabet's Google Life Sciences research unit, recently rebranded Verily...

Read More »

Low-Carb on Trial (Galileo Had It Easy)

Nora Gedgaudas | Primal Body Primal Mind | November 14, 2016

A recent exposé in the New York Times[1] revealed massive and pervasive fraud and collusion between the sugar industry and certain medical authorities in the 1960’s designed to erroneously promote saturated fat as the culprit behind heart disease. Effectively diverting attention from the real source of the problem (the increasing consumption of dietary sugar), the food industry conspired with key authorities within the medical establishment to serve their own best interests at the expense of public health.  Historic documents showed that they were intentionally concealing the fact that sugar, instead of fat, was knowingly to blame...

Read More »

Stanford’s John Ioannidis On “Underperforming Big Ideas”

Press Release | Stanford Medicine | July 28, 2016

In a thought-provoking JAMA commentary out today, Stanford’s John Ioannidis, MD, DSc, and two colleagues call for biomedical researchers — and funding institutions — to “sunset underperforming initiatives.” Nothing controversial there, until you go on to read that some of those initiatives are in the popular fields of gene therapy, stem cell therapy or precision medicine. And, they write, perhaps some less-successful projects have been pursued simply because they fall within a top research field.

Read More »